157 results on '"Ambinder, Alexander"'
Search Results
2. Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide
3. Graft Failure Incidence, Risk Factors, and Outcomes in Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide
4. HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age
5. Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience
6. Multi-drug algorithm to accurately predict best first-line treatments in newly-diagnosed acute myeloid leukemia (AML).
7. Allogeneic Hematopoietic Cell Transplantation with Non-Myeloablative Conditioning and Post-Transplant Cyclophosphamide Prophylaxis in Patients with Reduced Systolic Function
8. Autoimmune disease in CMML-the chicken or the egg?
9. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source
10. Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 Years
11. Allogeneic Hematopoietic Cell Transplantation with Non-Myeloablative Conditioning and Post-Transplant Cyclophosphamide Prophylaxis in Patients with Reduced Systolic Function
12. Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation
13. Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis
14. Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide
15. Bone marrow niche chemoprotection of metastatic solid tumors mediated by CYP3A4
16. Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease
17. Modified Ham test for atypical hemolytic uremic syndrome
18. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source
19. Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 Years
20. Post-Remission Outcomes in Patients with Acute Myeloid Leukemia (AML) Are Similar between Hypomethylating Agent/Venetoclax Therapy and Intensive Chemotherapy after Accounting for Measurable Residual Disease (MRD) Status
21. Outcomes of Patients with TP53-Mutated Myeloid Neoplasms (TP53-MN) and the Role of Allogenic Blood or Marrow Transplantation (alloBMT)
22. Prognostic Impact of Secondary Versus De Novo Ontogeny in Acute Myeloid Leukemia (AML) Is Predominantly Accounted for By the European Leukemianet (ELN) 2022 Risk Classification
23. Gemtuzumab Ozogamicin for Cytoreduction in Hyperleukocytosis
24. Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)
25. Pre- and Post-Transplant Measurable Residual IDH Mutations Are Not Associated with Relapse in Patients with IDH-Mutated AML
26. Reply: Not All Inhaled Medicines Are Equal
27. Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia
28. The Promise of Retinoids in the Treatment of Cancer: Neither Burnt Out Nor Fading Away.
29. Allogeneic Blood or Marrow Transplantation with Post-transplantation Cyclophosphamide for Peripheral T-cell Lymphoma: Importance of Graft Source
30. Mismatched donor transplantation with post-transplantation cyclophosphamide for advanced cutaneous T-cell lymphoma: a single-center retrospective study
31. Small Devices, Big Problems: Addressing the Global Warming Potential of Metered-Dose Inhalers
32. AML-691 Waiting for Mutational Test Results Does Not Delay Time to Treatment for Newly Diagnosed AML Ineligible for Intensive Chemo
33. Waiting for Mutational Test Results Does Not Delay Time to Treatment for Newly Diagnosed AML Ineligible for Intensive Chemo
34. Mismatched donor transplantation with post-transplantation cyclophosphamide for advanced cutaneous T-cell lymphoma: A single-center experience.
35. Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy
36. Persistent IDHmutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide
37. Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab
38. Response Prediction to Isocitrate Dehydrogenase (IDH) Inhibitors in Patients with IDH1- or IDH2-Mutated Acute Myeloid Leukemia Using Clinical and Genomic Data
39. Incorporating Gemtuzumab into the Treatment of Core Binding Factor Acute Myeloid Leukemia: A Single Center Experience
40. Favorable Outcomes for High-Risk MDS and Oligoblastic AML with MDS-Related Changes with Reduced Intensity Allogeneic Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide
41. Iadademstat and Gilteritinib for the Treatment of FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia: The Frida Study
42. Residence proximity to benzene release sites is associated with increased incidence of non-Hodgkin lymphoma
43. Using primary site as a predictor of survival in mantle cell lymphoma
44. Transplant Outcomes for IDH-Mutated AML: Good Outcomes Thanks to Keeping Good Company
45. A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML
46. Potential targeting of FLT3 acute myeloid leukemia
47. CHIPs-A-LOY Loss of Chromosome Y Clusters With CHIP-associated Mutations
48. Ibrutinib‐associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins
49. Carotidynia Heralding the Onset of Acute Leukemia
50. β-2-Glycoprotein Antibodies Activate the Alternative Pathway of Complement in Antiphospholipid Antibody Syndrome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.